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Abstract
Background—Biomarker variability, which includes within-individual variability (CVI), 
between-individual variability (CVG) and methodological variability (CVP+A) is an important 
determinant of our ability to detect biomarker-disease associations. Estimates of CVI and CVG 
may be population specific and little data exists on biomarker variability in diverse Hispanic 
populations. Hence, we evaluated all 3 components of biomarker variability in the Hispanic 
Community Health Study/Study of Latinos (HCHS/SOL) using repeat blood collections (n=58) 
and duplicate blood measurements (n = 761 – 929 depending on the biomarker).
Methods—We estimated the index of individuality (II) ((CVI+CVP+A)/CVG) for 41 analytes and 
evaluated differences in the II across sexes and age groups.
Results—Biomarkers such as fasting glucose, triglycerides and ferritin had substantially higher 
inter-individual variability and lower II in HCHS/SOL as compared to the published literature. We 
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also found significant sex-specific differences in the II for neutrophil count, platelet count, 
hemoglobin, % eosinophils and fasting glucose. The II for fasting insulin, post oral glucose 
tolerance test glucose and cystatin C was significantly higher among the 18–44 y age group as 
compared to the 45+ y age group.
Conclusions—The implications of these findings for determining biomarker- disease 
associations in Hispanic populations need to be evaluated in future studies.
Keywords
Analytical variation; biomarker variability; Hispanics
INTRODUCTION
Reliable measurement of biomarkers and ability to compare changes in biomarker values 
over time is of great importance to epidemiological studies that are designed to evaluate 
cross sectional and longitudinal changes in the incidence and prevalence of various diseases. 
Thus, it is important for epidemiological studies to estimate the background variation of 
biomarkers. The Hispanic Community Health Study/Study of Latinos (HCHS/SOL) is a 
population-based cohort study designed to examine risk factors for chronic diseases such as 
cardiovascular disease (CVD), stroke, asthma, chronic obstructive lung disease, sleep 
disorders, dental caries and periodontal disease, hearing impairment and tinnitus, diabetes, 
kidney and liver disease, and cognitive impairment. The HCHS/SOL recruited 16415 self-
identified Hispanic/latino adults (Cuban, Dominican, Mexican, Puerto Rican, Central 
American, and South American backgrounds) aged 18 to 74 y from randomly selected 
households in four US communities (Bronx, New York; Chicago, Illinois; Miami, Florida; 
San Diego, California) between March 2008 and June 2011. Details about the sample design 
and cohort selection have been previously described [1]. Fasting blood samples, an oral 
glucose tolerance test and spot urine samples were collected for measurement of various 
biomarkers that included liver enzymes such as serum alanine aminotransferase (ALT), 
aspartate aminotransferase (AST), γ- glutamyl transferase (GGT), kidney function 
biomarkers such as serum creatinine, cystatin C, urinary creatinine, microalbumin and 
urinary albumin/creatinine ratio, lipid biomarkers such as serum total cholesterol, 
triglycerides, high density lipoprotein cholesterol (HDL-C), and low density lipoprotein 
cholesterol (LDL-C), diabetes related biomarkers such as glycated hemoglobin, fasting/post 
oral glucose tolerance test glucose and insulin, iron related biomarkers such as serum total 
iron, serum ferritin, serum transferrin and total iron binding capacity, inflammatory 
biomarkers such as, high sensitive C reactive protein (hsCRP), and a complete blood count 
with differential white blood cell count.
Previous studies have shown that linear and logistic regression models that are commonly 
used in the analysis of epidemiological data, produce biased estimates of the association 
between biomarker and disease outcomes when the biomarker has low repeatability [2]. The 
major sources of variability in biomarker measurement include within-individual variability, 
between-individual variability and methodological variability. The methodological 
variability encompasses (a) process (pre-analytical) variability such as variability in blood 
drawing, field center processing (including centrifuging and freezing) and shipping (b) 
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laboratory assay (analytical) variability and (c) post-analytical variability (e.g. errors in data 
transmission etc.). Though there are several studies evaluating the sources of variability for a 
large number of biomarkers [3–6] in predominantly Caucasian populations, only limited data 
are available on the variability of biomarkers in a diverse Hispanic population [7–11]. While 
methodological variability can be improved by better analytical techniques and 
standardization of biospecimen collection and processing procedures, between and within 
individual variability may be determined by the characteristics of the population being 
studied and likely will differ across various epidemiological studies. Since the repeatability 
of a biomarker measurement determines its association with disease outcomes in 
epidemiological studies, the HCHS/SOL conducted a study to estimate the within-individual 
biologic variability, between-individual variability and methodological variability in the 
HCHS/SOL biomarker measurement.
MATERIAL AND METHODS
Study Design
IRB approval for the HCHS/SOL study was obtained at each field center, the coordinating 
center and the central laboratory. Fasting blood samples were obtained following a 
standardized venipuncture protocol by staff at the HCHS/SOL baseline clinic visit. 
Approximately 80 ml of blood and 10 ml of urine specimens were collected according to the 
standardized protocol [12,13]. All biospecimens were processed at the field centers into 
multiple 500 μl serum and plasma aliquots and frozen at −80°C. The serum tubes were kept 
at room temperature for 30–45 min prior to centrifugation to allow for clotting while the 
citrate and EDTA anticoagulated plasma tubes were processed within 15 min of blood 
collection. The anticoagulated tubes were centrifuged at 3000 × g for 30 min at 15°C while 
the serum tubes were centrifuged at 3000 × g for 10 min at 15°C. Urine samples were kept 
refrigerated after collection at 4°C and processed within 12 h of collection. After thoroughly 
mixing the urine samples aliquots of neutral urine, alkaline and acidic urine were prepared 
and frozen at −80°C. Frozen specimens were shipped on dry ice to the central laboratory at 
the University of Minnesota weekly. The frozen aliquots were used to analyze a variety of 
biochemical markers at baseline [12]. An unprocessed EDTA tube was shipped daily at 4°C 
to the central laboratory for measurement of complete blood counts. The central laboratory 
maintains a biorepository of plasma, serum, genomic DNA, RNA and urine for future 
analysis. The HCHS/SOL QC committee implemented the Within-Individual Variation study 
(all procedures and most questionnaires) in 58 volunteer participants to estimate the within-
individual variability. In addition, the study implemented the Sample Handling study to 
obtain 5% duplicate biospecimens to monitor over time the variability in the measurement of 
various biochemical analytes. A detailed description of all the analytes measured in this 
study can be found in study manual 7a publically available at https://www2.cscc.unc.edu/
hchs/manuals-forms.
Within-Individual Variation study—Following the HCHS/SOL protocol, all blood and 
urine samples were collected from 58 participant volunteers (Bronx (n=14), Chicago (n=12), 
Miami (n=15), and San Diego (n=15)) at 2 time points; first at baseline and then 
approximately a little over a month later. The repeatability study started 6 months after 
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HCHS/SOL baseline clinic start-up and recruitment was completed over 30 months. One 
individual in this study had end stage renal disease, six individuals had self-reported history 
of diabetes and all other participants were healthy volunteers. This study recruited equal 
numbers of men and women between the ages of 18–44 and 45–74.
Sample Handling study—Over the entire HCHS/SOL study collection period (36 
months), a QC duplicate sample was obtained during the participant’s clinic visit by either 
drawing 1 to 3 additional tube(s) of blood, or by dividing a urine sample into separate 
containers. The QC duplicate samples were collected after all the study samples (9 blood 
tubes and 1 urine specimen) were collected. The tourniquet was released within 2 min to 
minimize hemoconcentration. The duplicate samples were then processed at the field centers 
using the same method as for the original samples. These additional duplicate specimens 
were labeled with a phantom participant ID that was indistinguishable from other ID 
numbers, so that the laboratory was blinded to the replicate samples. In other words, the 
Sample Handling study did not collect duplicate collections for all 10 tubes for from a single 
participant. Instead, six participants were needed to provide a complete set of 10 QC 
duplicate specimens for a phantom ID. Therefore, 3,980 participants contributed to the pool 
of 5,545 duplicate specimens with 432 individuals contributing 2 specimens and 38 
contributing three specimens. A duplicate urine sample required that the participant provide 
at least 15 ml of urine. A total of 12 ml were divided among six 2.0 ml vials for 
determination of creatinine and albumin levels by the Central Laboratory, and four aliquots 
were stored for future analyses. Thus, depending on the biomarker, 761 to 929 HCHS/SOL 
participants contributed duplicate samples for the Sample Handling Study. For data analysis, 
results on each duplicate specimen were matched to the corresponding participant results at 
the Coordinating Center using the Phantom ID Form which links both IDs completed by 
field center technicians.
STATISTICAL ANALYSIS
Before any analysis was done on the Sample Handling Study and the Within-Individual 
Variation Study, the data was initially screened for possible mismatches (e.g., sample 
mislabeling) and excluded from further analyses. Biomarkers with skewed distributions were 
log-transformed. We used scatterplots and Bland-Altman plots to visually check linearity 
and constant variance, and to identify outliers (defined as difference from mean > 3SD). 
Analyses reported exclude outliers. The biomarker’s total variance (σ2) was partitioned into 
3 components: the within-individual variance (σ2I), the between-individual variance (σ2W) 
and the methodological variance (σ2P+A; combination of process and analytical variance). 
Specifically, we used data from the Within-Individual Variation Study to estimate the total 
within-individual variance (σ2I) (which includes both biological variation within individuals 
and methodological variation) and data from the Sample Handling study to estimate both the 
between-individual variance (σ2G) and methodological variance (σ2P+A). We used the 
Sample Handling Study to estimate between-individual variability in the HCHS/SOL since 
the Sample Handling Study was a random sample of the HCHS/SOL cohort and more 
closely mirrors the biomarker distribution in the HCHS/SOL cohort. These three variance 
components were estimated using linear mixed models with random intercepts using 
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maximum likelihood estimation[14], an extension of the ANOVA models used 
previously[15] that assumes our participants come from a random sample of a larger 
population about whom we want to make inference. While the model structure, as seen 
below, was identical it is important to note that 2 separate models were fit, one for the 
Within-Individual Variation Study and one for the Sample Handling Study. Thus, the 
definition of Yij, as defined as the jth biomarker measurement on the ith individual, was 
different in the Within-Individual Variation and Sample Handling studies. Albumin/
creatinine ratio was highly skewed and hence was log-transformed. The between-individual 
variance was the variance of the random effect term, b0i, and the within-individual variance 
and the methodological variance were estimated as the variance of the random error term eij.
The process and analytical variance was assumed to include both the process (pre and post-
analytical) and laboratory assay (analytical) variability. However, we were able to calculate 
the laboratory assay (analytical) variability (σ2A) using the observed variability in biomarker 
measurement in control samples (independent from the study samples) that were analyzed in 
at least 20 consecutive analytical runs prior to start of the study. The assay performance was 
monitored during the course of the study using laboratory controls and participation in 
external proficiency tests through the College of American Pathology (CAP). These control 
samples showed that the assay performance remained unchanged during the duration of the 
study. For each biomarker, we estimated the within-individual coefficient of variation (CVI) 
based on data from the Within-Individual Variation Study as the standard deviation (the 
square root of the within-individual variance component) multiplied by 100 and divided by 
the average value (the average value being the mean of the average of the original and the 
repeat measurement). Similarly, the between-individual and process and analytical 
coefficient of variation (CVG and CV P+A respectively) were estimated based on data from 
the Sample Handling Study. In the case of the between-individual variation, the mean value 
used to calculate the CV was the mean value of the blinded duplicate data. The process and 
analytical CV (CVP+A) was estimated using the standard deviation expressed as a percent of 
the mean of the blinded duplicate pairs. We used these CV values to estimate desirable 
imprecision (CVI/2), desirable bias (0.25*[(CVI)2 +(CVG)2]1/2) and total error 
(1.65*(desirable imprecision) + (desirable bias)). We calculated a statistic commonly used in 
clinical pathology literature called the index of individuality (II)[15] using the equation II = 
(SI+SP+A)/SG where SG + SP+A = (CV2I+ CV2P+A)1/2 and SG = (CV2G)1/2. Finally we 
performed all the above described analyses stratified by sex and age group (18–44 and 45–
74 y). To test for significant differences in the index of individuality between sex and age 
groups, an approximate permutation test was conducted using 500 rearrangements of the 
dataset [16]. Reassignments of both age and gender categories were done by random 
assignment while ensuring the age and gender distributions were identical to the true 
population. An α level of 0.05 was used to determine statistical significance.
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RESULTS
Table 1 shows the within-individual variability (CVI), the between-individual variability 
(CVG), the combined process and analytical variability (CVP+A) and the analytical 
variability (CVA) for all the biomarkers measured at HCHS/SOL baseline. Overall, most of 
the biomarkers met one of the most widely used criteria for acceptable level of analytical 
precision (CVA < desirable imprecision), with the exception of serum cystatin (2.9% vs. 
2.6%), serum creatinine (4.1% vs. 3.6%) and total iron binding capacity (TIBC) (2.7% vs.
2.3%). The overall process and analytical error was lower than the total error (1.65* 
desirable imprecision + desirable bias) for all the analytes. The index of individuality ranged 
from 0.11 to 1.36 indicating a relatively large range across all these analytes. Subsequently, 
we compared the CVI, CVG and the index of individuality observed in HCHS/SOL with the 
corresponding values in NHANES or other published studies (Table 2). A majority of 
analytes showed substantially higher CVG in HCHS/SOL as compared to previously 
published studies while the CVI in HCHS/SOL was comparable to published literature 
(Table 2). This is reflected by the lower II in HCHS/SOL as compared to other studies 
(Table 2). The index of individuality did not differ substantially for the majority of the 
analytes across both sexes with some exceptions (Table 3). The index of individuality was 
significantly lower in women as compared to men for neutrophil count ((0.47 vs. 0.94; 
p=0.002), fasting insulin (0.32 vs. 0.58; p<0.0001), platelet count (0.28 vs. 0.40; p=0.02) 
and hemoglobin (0.36 vs. 0.48; p=0.04). The index of individuality was significantly higher 
among women as compared to men for fasting glucose (0.21 vs. 0.10; p=0.03) and % 
eosinophils (0.54 vs. 0.32; p=0.04). Though not statistically significant, the index of 
individuality for urinary creatinine was also substantially higher among women as compared 
to men (0.93 vs. 0.56; p=0.07). Analysis stratified by age group (18–44 vs. 45+ y) showed 
that the index of individuality was significantly higher among the 18–44 y age group as 
compared to the 45–74 age group for fasting insulin (0.57 vs. 0.30; p=0.002), post OGTT 
glucose (0.80 vs. 0.43; p=0.002), logarithmically transformed urinary albumin/creatinine 
ratio (0.66 vs. 0.27; p=0.002) and cystatin C (0.35 vs. 0.23; p=0.03) (Table 4).
DISCUSSION
This study found that the between-individual variability was substantially higher in the 
HCHS/SOL population as compared to published literature [4] including NHANES [17] 
while the within-individual variability was comparable to other studies. These findings are 
also reflected in the substantially lower index of individuality in HCHS/SOL as compared to 
other studies. Notable examples of analytes with the substantially higher CVG and lower 
index of individuality in HCHS/SOL as compared to the published literature and the 
variability estimates from the NHANES study include fasting glucose, triglycerides and 
ferritin. The index of individuality for these biomarkers was 0.16, 0.29 and 0.19 respectively 
in the HCHS/SOL while the corresponding values in the published literature are 0.66–0.78 
[4, 17], 0.51–0.61 [4,17] and 0.95 [4]. Small sample sizes in many studies evaluating 
biomarker variability, exclusive inclusion of patients on treatment for certain biomarkers 
(e.g. inclusion of diabetics for estimating variability in glucose), variability between 
different assays used for measurement of analytes and inclusion of hospital based samples as 
compared to a random subset of the general population) are possible explanations for the 
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observed differences. However, our study also included some individuals with diabetes, mild 
elevation of liver enzymes and/or end stage renal disease. So inclusion of patients with 
clinical disease alone is not sufficient to explain the observed differences. Differences in 
study design, where estimates for CVI and CVG were obtained from different participants in 
HCHS/SOL while several of the other studies obtained estimates for CVI and CVG from the 
same participants is another potential explanation for the observed differences. A study 
design similar to that used in HCHS/SOL is also commonly used in several epidemiological 
studies such as NHANES [17–19] and the Atherosclerosis Risk in Communities (ARIC) 
[11] as CVG estimates can usually be obtained on a much larger group of people as 
compared to the CVI The NHANES, [17–19] which is a population-based study and 
estimated CVI and CVG from different participants also reported different estimates for 
some biomarkers as compared to HCHS/SOL. This suggests that the time interval between 
the 2 measurements to estimate within-individual variability (average of 19 days in 
NHANES as compared to an average of 44 days in HCHS/SOL) and racial/ethnic 
differences in the 2 populations (majority non-Hispanic whites in NHANES) are other 
possible explanations for the observed differences in variability observed for various 
analytes. The CVI estimate in HCHS/SOL and NHANES is also limited by the nonrandom, 
self-selected design and may also contribute to the observed differences between the 2 
studies.
In the context of clinical medicine, as formally evaluated by Harris [20], when the index of 
individuality for a particular biomarker is low (<0.6), the participant’s test results stay within 
the population-based reference range. In the context of epidemiological studies, the lower 
index of individuality (and corresponding higher reliability coefficients) suggest that single 
point measurements of these analytes may more accurately reflect long term homeostatic set 
points for these analytes [15] in the diverse Hispanic population as compared to other racial/
ethnic subgroups. Participants in the HCHS/SOL study have substantially higher between-
individual variability as compared to published data while the within-individual variability 
estimates were similar to published literature The higher between-individual coefficients of 
variability observed in HCHS/SOL may also indicate substantial heterogeneity in biomarker 
distributions across Hispanic backgrounds. However, the design of the HCHS/SOL study 
where people with specific Hispanic backgrounds were recruited from specific field centers 
does not allow us to completely distinguish between field center specific effects and 
Hispanic background group effects. The immediate implications of the lower index of 
individuality (conversely higher reliability coefficient) is that epidemiological studies in 
diverse Hispanic populations may require smaller sample sizes to detect significant 
associations of magnitudes similar to those detected in other populations and that adjustment 
for Hispanic background may be necessary to minimize confounding of any observed 
biomarker-disease associations.
As previously reported in published literature, we confirmed lower mean levels of several 
biomarkers such as hemoglobin [21], neutrophil count [22,23] and fasting glucose [24] 
among women as compared to men while women had higher platelet count [23, 25] and 
fasting insulin levels as compared to men. Though no previous studies have reported higher 
mean fasting insulin concentrations among women as compared to men, a previous study 
has shown higher insulin sensitivity among women as compared to men [26]. We also 
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observed sex specific differences in the index of individuality, with fasting glucose having 
significantly higher index of individuality among women as compared to men while 
hemoglobin, platelet count, neutrophil count and fasting insulin all having lower index of 
individuality among women as compared to men. The NHANES reported no sex-specific 
differences in the index of individuality for fasting glucose or the hematological parameters 
such as hemoglobin, platelet count and neutrophil count [19]. In contrast, the NHANES 
reported sex specific differences in the between-individual variance for several analytes such 
as ferritin, creatinine and ALT though no sex specific differences were noted in the HCHS/
SOL[18],[19]. These results suggest that, at least for some commonly used biomarkers, sex 
specific differences in the index of individuality and reliability coefficient may affect ability 
to detect associations of similar magnitude between a biomarker and an outcome in the 2 
sexes in a diverse Hispanic population. This study also demonstrates higher index of 
individuality among younger individuals as compared to older age groups for fasting insulin, 
cystatin C, logarithmically transformed urinary albumin/creatinine ratio and OGTT glucose. 
These findings are consistent with previously published data on serum creatinine that shows 
inter-individual variability for serum creatinine increasing with age[27]. However, given the 
large number of comparisons made in this study, these findings need to be confirmed in 
other studies. Both the NHANES and the HCHS/SOL studies found no differences in the 
index of individuality across age groups for the hematological parameters evaluated in both 
the studies [18].
We also evaluated the specific components of process and analytical variability by 
separating out the analytical variability (CVA) and the variation due to the pre-analytical 
differences in processing of blood samples. For most analytes, the pre-analytical variation is 
minimal and a majority of the analytical variation (60%–100%) is due to analytical 
measurement error and reflect the rigorous implementation of standardized protocols for 
collection and processing of biospecimens in the HCHS/SOL. Few specific analytes, such as 
the urinary albumin/creatinine and high sensitivity CRP remain sensitive to small variations 
in collection and processing of biospecimens and procedures. Further refinement of the 
protocol to minimize the time delay between urine collection and processing of urinary 
specimens may lead to lower process and analytical variation for the urinary analytes. A 
majority of the hematological variables show that approximately half of the overall 
methodological variability is due to pre-analytical variation in this study. In the HCHS/SOL, 
the whole blood samples were shipped to the central laboratory within 24–72 hours after 
collection and complete blood counts were performed in a central laboratory. The sample 
shipping to the central laboratory likely increases the contribution of pre-analytical variation 
to the overall method variation. Hence this observation for the hematological variables may 
not be applicable to other clinical scenarios where the blood is processed soon after sample 
collection. Of note, cystatin C and creatinine, 2 widely used measures to estimate kidney 
function, showed that the analytical variability of these assays were higher than the optimal 
imprecision estimated by the within person variability. Both cystatin C and creatinine were 
measured in a CLIA certified laboratory and results of external proficiency testing 
(performed every 3 months) for both analytes showed that the results were within acceptable 
limits for both analytes with no evidence of long term laboratory assay shifts or drifts. Intra-
individual CV and inter-individual CVs are properties of the population being studied and 
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can vary based on population characteristics (age, sex, ethnic distribution etc.). Thus, though 
the analytical CVs for the cystatin C and serum creatinine were within acceptable limits in 
terms of analytical precision as estimated by the external proficiency testing samples and 
similar to the analytical CVs reported in NHANES (serum creatinine: 4.1% in HCHS/SOL 
vs. 4.6% in NHANES), based on the distribution of the intra-individual and inter-individual 
CVs, the analytical goals for the HCHS/SOL study demand more stringent control of 
analytical variation for these 2 analytes. This highlights an important issue; while it is 
desirable for all analytes to meet these analytical goals, some of the currently available in-
vitro diagnostics methods may not be able to meet the specifications for individual research 
studies. As described previously the higher analytical variability in serum creatinine may 
lead to clinical misinterpretation of creatinine based eGFR values that are used for staging 
chronic kidney disease [28]. The impact of higher analytical variability on the ability of the 
HCHS/SOL study to accurately classify participants into various categories of kidney 
function needs to be further evaluated.
In summary, our study shows significant differences in parameters such as the index of 
individuality and the reliability coefficient between the diverse Hispanic population in 
HCHS/SOL and the published literature. We further document sex and age specific 
differences for many biomarkers in this Hispanic population. The implications of these 
findings for determining associations between biomarkers and various disease outcomes, 
repeated measurement of several biomarkers and disease classification need to be evaluated 
in future studies.
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Highlights
• There is little data on background biomarker variability in Hispanic 
populations.
• US based Hispanics show higher between-person variability for several 
biomarkers.
• US based Hispanics also show lower index of individuality for several 
biomarkers.
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